A detailed history of Foundry Partners, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Foundry Partners, LLC holds 103,782 shares of ABBV stock, worth $18.2 Million. This represents 1.05% of its overall portfolio holdings.

Number of Shares
103,782
Previous 104,480 0.67%
Holding current value
$18.2 Million
Previous $17.9 Million 14.36%
% of portfolio
1.05%
Previous 0.97%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$163.84 - $199.33 $114,360 - $139,132
-698 Reduced 0.67%
103,782 $20.5 Million
Q2 2024

Aug 05, 2024

BUY
$154.79 - $180.76 $15.7 Million - $18.4 Million
101,700 Added 3658.27%
104,480 $17.9 Million
Q1 2024

May 08, 2024

SELL
$159.82 - $182.1 $82,307 - $93,781
-515 Reduced 15.63%
2,780 $506,000
Q3 2023

Nov 09, 2023

SELL
$133.59 - $154.65 $74,142 - $85,830
-555 Reduced 14.42%
3,295 $491,000
Q2 2023

Jul 12, 2023

BUY
$132.51 - $164.9 $82,818 - $103,062
625 Added 19.38%
3,850 $518,000
Q3 2022

Oct 21, 2022

BUY
$134.21 - $153.93 $97,302 - $111,599
725 Added 29.0%
3,225 $433,000
Q2 2022

Jul 28, 2022

SELL
$137.62 - $174.96 $417,676 - $531,003
-3,035 Reduced 54.83%
2,500 $383,000
Q4 2021

Jan 26, 2022

BUY
$107.43 - $135.93 $35,344 - $44,720
329 Added 6.32%
5,535 $749,000
Q3 2021

Oct 14, 2021

SELL
$106.4 - $120.78 $67,776 - $76,936
-637 Reduced 10.9%
5,206 $562,000
Q2 2021

Jul 23, 2021

BUY
$105.21 - $117.21 $15,781 - $17,581
150 Added 2.63%
5,843 $658,000
Q4 2020

Feb 04, 2021

SELL
$80.49 - $108.67 $9.61 Million - $13 Million
-119,423 Reduced 95.45%
5,693 $610,000
Q3 2020

Oct 23, 2020

BUY
$85.91 - $100.83 $10.5 Million - $12.4 Million
122,487 Added 4659.07%
125,116 $11 Million
Q2 2020

Aug 03, 2020

BUY
$73.37 - $98.18 $192,889 - $258,115
2,629 New
2,629 $258,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Foundry Partners, LLC Portfolio

Follow Foundry Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Foundry Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Foundry Partners, LLC with notifications on news.